The Current and Future Roles of Precision Oncology in Advanced Breast Cancer

Abstract

Learning Objectives: On successful completion of this activity, participants should be able to (1) define prognostic and predictive imaging biomarkers and name at least 1 prognostic and predictive imaging biomarker for advanced breast cancer; (2) list the current roles of18F-FDG PET/CT imaging in advanced breast cancer; and (3) list 3 non–18F-FDG radiotracers that may serve as imaging biomarkers in advanced breast cancer. Financial Disclosure: Dr. Jacene is a consultant for Blue Earth Diagnostics and Spectrum Dynamics Ltd.; receives research support from Blue Earth Diagnostics, Inc. (to the institute); received speaker honoraria from ITM and Monrol; and receives royalties from Cambridge University Press. Dr. Specht receives research support from Lyell Immunopharma, Merck, Cascadian Therapeutics, Pfizer, Seattle Genetics, Genentech, Xencor, Abbvie, Inc., Celcuity, Inc., Novartis, Myriad Pharmaceuticals, AstraZeneca, and Carisma Therapeutics; is a consultant for GE Healthcare, Sensei Biotherapeutics, Lyell Immunopharma, A2 Biotherapeutics, and Volastra; is on the advisory board for Daiichi Sankyo, GlaxoSmithKline, GE Healthcare, Sensei Biotherapeutics, and Lyell Immunopharma; and is an investigative meeting participant for A2 Biotherapeutics. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through March 2027.